We are pleased to be featured as #SMEoftheWeek on Digital Health London Accelerator social channels
- Jul 28, 2022
- 1 min read
They highlight how Panakeia is changing the way biomarker testing is done through the use of #AI. Read more...
top of page
Search
CAMBRIDGE, UK — April 21, 2026 — Panakeia (“the Company”), the world’s first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for
Cambridge, UK, 16 April 2026 – Panakeia (“the Company”), the world’s first in silico multi-omics company, is pleased to confirm that it will be attending and presenting at a number of conferences in
· Largest real-world, blinded, multi-site validation of AI molecular profiling from routine diagnostic images · Software identifies clinically actionable cancer biomarkers in minutes rathe
bottom of page